| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3187648 | Annales de Dermatologie et de Vénéréologie | 2013 | 10 Pages |
Abstract
Moreover, the year 2013 was marked by the increasing knowledge in the management of adverse events induced by these new treatments. In the field of basal cell carcinoma, after the publication of large scale studies, vismodegib, the inhibitor of the hedgehog signalling pathway, was approved by the European Medicines Agency.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
G. Quéreux,